Coya Therapeutics Inc (NASDAQ: COYA) has experienced a rise in its stock price by 12.17 compared to its previous closing price of 6.00. However, the company has seen a gain of 9.08% in its stock price over the last five trading days. businesswire.com reported 2025-02-25 that HOUSTON–(BUSINESS WIRE)–Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. and Dr. Stanley H. Appel, Professor of Neurology, Houston Methodist Hospital will participate in a BTIG hosted KOL webcast “Is Alzheimer’s next for GLP-1s and Combos?” on February 27, 2025 to discuss the potential treatment of Al.
Is It Worth Investing in Coya Therapeutics Inc (NASDAQ: COYA) Right Now?
The 36-month beta value for COYA is also noteworthy at 0.50. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for COYA is 15.53M, and at present, short sellers hold a 1.67% of that float. The average trading volume of COYA on February 28, 2025 was 75.78K shares.
COYA’s Market Performance
The stock of Coya Therapeutics Inc (COYA) has seen a 9.08% increase in the past week, with a 15.83% rise in the past month, and a 3.54% gain in the past quarter. The volatility ratio for the week is 9.62%, and the volatility levels for the past 30 days are at 7.98% for COYA. The simple moving average for the past 20 days is 4.51% for COYA’s stock, with a 1.57% simple moving average for the past 200 days.
Analysts’ Opinion of COYA
Many brokerage firms have already submitted their reports for COYA stocks, with D. Boral Capital repeating the rating for COYA by listing it as a “Buy.” The predicted price for COYA in the upcoming period, according to D. Boral Capital is $15 based on the research report published on December 04, 2024 of the previous year 2024.
COYA Trading at 12.17% from the 50-Day Moving Average
After a stumble in the market that brought COYA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.04% of loss for the given period.
Volatility was left at 7.98%, however, over the last 30 days, the volatility rate increased by 9.62%, as shares surge +15.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +15.64% upper at present.
During the last 5 trading sessions, COYA rose by +9.08%, which changed the moving average for the period of 200-days by -20.45% in comparison to the 20-day moving average, which settled at $6.44. In addition, Coya Therapeutics Inc saw 17.45% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at COYA starting from SNYDER DAVID S, who purchase 1,800 shares at the price of $7.19 back on Nov 14 ’24. After this action, SNYDER DAVID S now owns 8,800 shares of Coya Therapeutics Inc, valued at $12,934 using the latest closing price.
Swaminathan Arun, the Chief Executive Officer of Coya Therapeutics Inc, purchase 5,000 shares at $7.36 during a trade that took place back on Nov 13 ’24, which means that Swaminathan Arun is holding 10,000 shares at $36,797 based on the most recent closing price.
Stock Fundamentals for COYA
Current profitability levels for the company are sitting at:
- -1.17 for the present operating margin
- 1.0 for the gross margin
The net margin for Coya Therapeutics Inc stands at -1.12. The total capital return value is set at -0.34. Equity return is now at value -50.83, with -45.10 for asset returns.
Currently, EBITDA for the company is -7.88 million with net debt to EBITDA at 2.74. When we switch over and look at the enterprise to sales, we see a ratio of 8.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.31.
Conclusion
In summary, Coya Therapeutics Inc (COYA) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
